Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
暂无分享,去创建一个
L. Staudt | W. Wilson | S. Steinberg | E. Jaffe | M. Raffeld | S. Pittaluga | N. Grant | K. Dunleavy | J. Janik | U. Hegde | B. Chabner | M. Gutiérrez | W. Wilson
[1] R. Green,et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR , 2007, Nature Immunology.
[2] Zhi-xiang Shen,et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. , 2007, Blood.
[3] R. Gascoyne,et al. Prognostic significance of p53/p21 expression in DLBCL treated with CHOP or R-CHOP: A correlative study of E4494 , 2007 .
[4] Carl Blomqvist,et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. , 2007, Blood.
[5] B. Bonavida,et al. ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’ , 2007, Oncogene.
[6] Andrew Lister,et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Gascoyne,et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2007, Blood.
[8] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Staudt,et al. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? , 2007, Blood.
[10] C. Burgaleta,et al. Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study , 2007, British journal of haematology.
[11] D. de Jong,et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). , 2006, Blood.
[12] W. Wilson,et al. Novel Treatment of Burkitt Lymphoma with Dose-Adjusted EPOCH-Rituximab: Preliminary Results Showing Excellent Outcome. , 2006 .
[13] A. Zelenetz,et al. Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. , 2006 .
[14] W. Wilson,et al. Drug resistance in diffuse large B-cell lymphoma. , 2006, Seminars in hematology.
[15] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Gascoyne,et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. , 2006, Blood.
[17] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[18] P. Gaulard,et al. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. , 2006, Haematologica.
[19] Enrica Morra,et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. , 2006, Haematologica.
[20] L. Staudt,et al. Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. , 2005 .
[21] K. Basso,et al. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells , 2005, Nature Immunology.
[22] Y. Jeon,et al. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non‐germinal centre B‐like diffuse large B‐cell lymphomas , 2005, Histopathology.
[23] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Vose,et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma , 2005, Leukemia & lymphoma.
[26] Ryan T. Phan,et al. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells , 2004, Nature.
[27] Kajia Cao,et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[28] 謙 大間知. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.Coiffier B,et al.N Engl J Med 2002;346(4):235-42--CHOP+リツキシマブ併用療法は、CHOP療法を上回る治療法であり、DLBCLの治療動向に大きなimpactを与えた , 2004 .
[29] R. Poon,et al. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms. , 2004, Molecular cancer therapeutics.
[30] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[31] L. Staudt,et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.
[32] P. Gaulard,et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.
[33] L. Staudt,et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. , 2002, Blood.
[34] P. O'Connor. Rituximab May Overcome bcl-2–Associated Chemotherapy Resistance in Untreated Diffuse Large B-Cell Lymphomas , 2002 .
[35] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[36] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[37] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[38] J. Darbon,et al. Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR. , 2001, Biochemical and biophysical research communications.
[39] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[40] D. Metcalfe,et al. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. , 2001, Blood.
[41] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[42] W. Wilson,et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. , 1997, Blood.
[43] Ellen,et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. , 1994, Blood.
[44] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[45] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[46] T. Lister,et al. The Cotswolds report on the investigation and staging of Hodgkin's disease. , 1990, British Journal of Cancer.
[47] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[48] H. Skipper,et al. EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. , 1964, Cancer chemotherapy reports.
[49] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[50] D.,et al. Regression Models and Life-Tables , 2022 .